中美福(fu)源成立(li)于2015年1月(yue)26日(有(you)限公司(si)成立(li)于2010年3月(yue)10日),公司(si)主要從事醫藥產品(pin)、技術的開發以及轉(zhuan)讓自有(you)技術。
公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)控股(gu)3個子公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si),分別(bie)是(shi)北京美福源生(sheng)物(wu)醫藥科(ke)(ke)技(ji)有限(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)、天津林達(da)生(sheng)物(wu)科(ke)(ke)技(ji)有限(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)和天津溥瀛生(sheng)物(wu)技(ji)術有限(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)。這(zhe)3個子公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)在(zai)股(gu)份公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)中分別(bie)承擔(dan)著新(xin)(xin)藥研(yan)(yan)(yan)發(fa)的(de)不同(tong)研(yan)(yan)(yan)究內容和階段性工作(zuo)(zuo)。公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)與(yu)子公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)一道以在(zai)中國(guo)開(kai)(kai)展原創原研(yan)(yan)(yan)國(guo)家1類新(xin)(xin)藥的(de)臨(lin)床前研(yan)(yan)(yan)究、臨(lin)床試驗研(yan)(yan)(yan)究和產業化作(zuo)(zuo)為公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)的(de)主(zhu)營業務。公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)正在(zai)開(kai)(kai)展中的(de)原創原研(yan)(yan)(yan)新(xin)(xin)藥均是(shi)以現有重(zhong)組蛋白質藥物(wu)的(de)長效化新(xin)(xin)藥研(yan)(yan)(yan)發(fa)為重(zhong)點。公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)與(yu)子公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)共同(tong)擁有這(zhe)個新(xin)(xin)藥研(yan)(yan)(yan)發(fa)技(ji)術平(ping)臺。
公司(si)還有(you)合資公司(si):天津福盈(ying)生(sheng)物制藥有(you)限公司(si)。
公司于(yu)2015年7月30日在新(xin)三板掛牌成功;證(zheng)券簡稱:中美(mei)福源,證(zheng)券代(dai)碼:833178。